Rare Benign Tumor Responds to Cancer Drug MedPage Today This double-blind, placebo controlled trial found that everolimus significantly decreased the volume of benign angiomyolipoma in the kidney in patients with tuberous sclerosis; placebo recipients showed no change. Adverse events with everolimus were ... |
